ClinicalTrials.gg
RecruitingNCT05668403Updated Apr 30, 2026

A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy

A Phase 1 interventional study of B007 and B007 in Primary Membranous Nephropathy, sponsored by Shanghai Jiaolian Drug Research and Development Co., Ltd. Recruiting at 6 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by Shanghai Jiaolian Drug Research and Development Co., Ltd · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 60 studies in Glomerulonephritis, Membranous with a site in China — 29 open to participants now, 37 under way, 10 of them phase 3. Glomerulonephritis, Membranous · China.

Planned enrollment
32nd of 50
52 · median 77
Started
2023
with 7 others
Phase 1
7 of 60
6 open now
Primary completion
2026-12
later than 13 of 36 live
Registered
26th of 60
by date
Lead sponsor
2 of 60
Shanghai Jiaolian Drug Research and Development Co., Ltd

Among the 60 studies in Glomerulonephritis, Membranous with a site in China, this one is the 32nd largest by planned enrollment of the 50 interventional ones that give a count, is one of 8 that started in 2023, is one of 7 in phase 1, reaches primary completion later than 13 of the 36 other live ones, and was the 26th registered.

Glomerulonephritis, Membranous

146 studies on the registry are indexed under Glomerulonephritis, Membranous; 60 are open to participants now.

Browse Glomerulonephritis, Membranous studies →

Open to participants now

29 of the 60 studies in Glomerulonephritis, Membranous with a site in China are open now. Recruiting first, the newest first:

23 more — sign in →

All 29 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 41 Glomerulonephritis, Membranous studies recruiting now, 14 (34%) set no upper age limit and 13 (32%) stop at 75 or younger; 8 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Glomerulonephritis, Membranous with a site in China, or all of them as a file.
02

Study summary

This Phase I Clinical Study assessed the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles and Preliminary Efficacy of Subcutaneous Injection of Recombinant Humanized Anti-CD20 Monoclonal Antibody in the Treatment of Primary Membranous Nephropathy

03

Conditions studied

  • Primary Membranous Nephropathy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects who have fully understood this study and voluntarily signed the form;
  2. Male or female subjects, aged between 18 and 75 years;
  3. Subjects with primary membranous nephropathy confirmed by renal ;
  4. Subjects with systolic blood pressure ≤ 140 mmHg and diastolic blood pressure ≤ 90 mmHg at screening;
  5. If taking ACEI(Angiotensin converting enzyme inhibitors), ARB(Angiotensin receptor blocker), a stable dose within 4 weeks before screening is required;
  6. Subjects who are able to follow the study protocol as judged by the investigator.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with secondary membranous nephropathy;
  2. Subjects with uncontrolled blood pressure as judged by the investigator within 3 months before screening;
  3. Subjects with decreases in urine protein ≥ 50% within 6 months before screening;
  4. Subjects who have received or are receiving renal replacement therapy;
  5. Subjects with type 1 diabetes mellitus, or those with type 2 diabetes mellitus who are diagnosed as diabetic nephropathy by percutaneous renal ;
  6. Subjects who have a clear history of tuberculosis or have received anti-tuberculosis treatment;
  7. Subjects with active bacterial, viral, fungal, mycobacterial, parasitic or other infections requiring systemic antibiotics or antiviral therapy;
  8. Subjects with known history of severe allergic reactions to humanized monoclonal antibodies;
  9. Subjects who received , major surgery, or participated in other clinical trials within 28 days before receiving the study drug;
  10. Pregnant or lactating women; women of who have not been sterilized do not agree to use appropriate measures during treatment and for at least 12 months after the last dose of the study drug;
  11. Subjects with serious, progressive, or uncontrolled disease that may increase risks during the participation in the study as assessed by the investigator;
  12. Subjects with a history of alcoholism or drug abuse within 12 months;
  13. Subjects with positive surface antigen; those with positive virus antibody; those with a history of immunodeficiency;
  14. Subjects with \< 300 cells/μL;
  15. Other conditions unsuitable for participation in this study determined by the Investigator.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
52 participants (estimated)

Study arms

  • Experimental
    B007:350mg

    B007:350mg Subcutaneous injection was administered on days 1 and 15 B007 matched Placebo Subcutaneous injection was administered on days 1 and 15

    Drug: B007

  • Experimental
    B007:700mg

    B007: 700mg Subcutaneous injection was administered on days 1 and 15 B007 matched Placebo Subcutaneous injection was administered on days 1 and 15

    Drug: B007

  • Experimental
    B007:1000mg

    B007: 1000mg Subcutaneous injection was administered on days 1 and 15 B007 matched Placebo Subcutaneous injection was administered on days 1 and 15

    Drug: B007

Interventions

  • DrugB007

    Drug: B007 injection Drug: Placebo injection

  • DrugB007

    Drug: B007 injection Drug: Placebo injection

  • DrugB007

    Drug: B007 injection Drug: Placebo injection

06

What researchers measure

Primary outcomes

  1. Dose limiting toxicity(DLT)

    Adverse reactions that are certainly or possibly related to the drug being tested during the dose escalation phase.

    Time frame: Approximately 1 years

  2. Security: Incidence of Treatment-Emergent Adverse Events

    Adverse event type, incidence, duration, correlation with study drug

    Time frame: Approximately 2 years

Secondary outcomes

  1. PK (Pharmacokinetics)

    Cmax

    Time frame: Approximately 1 years

  2. PK (Pharmacokinetics)

    Tmax

    Time frame: Approximately 1 years

  3. PK (Pharmacokinetics)

    AUC0-last(Area Under Curve of 0-last)

    Time frame: Approximately 1 years

  4. Biomarkers

    Changes in serum anti-PLA2R(Antiphospholipase A2 receptor) antibody levels relative to baseline

    Time frame: Approximately 1 years

  5. Immunogenicity

    Incidence of ADA(Adenosine deaminase)

    Time frame: Approximately 1 years

  6. Dynamics of pharmacodynamics

    Changes of peripheral blood CD19+B cells(B-lymphocyte antigen CD19) relative to baseline

    Time frame: Approximately 1 years

  7. Proportion of subjects achieving clinical remission

    Proportion of subjects achieving clinical remission

    Time frame: Approximately 2 years

07

Study locations

6 of 6 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2023 (actual). Primary completion is estimated for Dec 2026, 45 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2022
First posted
Dec 29, 2022
StartActual
Mar 2, 2023
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2027
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05668403
Lead sponsor
Shanghai Jiaolian Drug Research and Development Co., Ltd
Responsible party
Sponsor
First posted
Dec 29, 2022
Start date
Mar 2, 2023
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Apr 30, 2026

Study contacts

Minghui Zhao
Contact
mhzhao@bjmu.edu.cn
0086-13501243815

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: B007

Start the discussion